{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:51:50Z","timestamp":1765486310261,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.braindev.2019.06.004","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T17:18:59Z","timestamp":1562260739000},"page":"790-795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term outcome of a group of Japanese children with myelin-oligodendrocyte glycoprotein encephalomyelitis without preventive immunosuppressive therapy"],"prefix":"10.1016","volume":"41","author":[{"given":"Naomi","family":"Hino-Fukuyo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Haginoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-8948","authenticated-orcid":false,"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Takai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7430-3942","authenticated-orcid":false,"given":"Manami","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Kure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2019.06.004_b0005","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/dmcn.13703","article-title":"Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes","volume":"60","author":"Duignan","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.braindev.2019.06.004_b0010","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.braindev.2019.06.004_b0015","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.braindev.2015.02.006","article-title":"Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies","volume":"37","author":"Hino-Fukuyo","year":"2015","journal-title":"Brain Dev"},{"issue":"9","key":"10.1016\/j.braindev.2019.06.004_b0020","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"23","author":"Borisow","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.braindev.2019.06.004_b0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.braindev.2019.06.004_b0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.braindev.2019.06.004_b0035","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.braindev.2019.06.004_b0040","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1212\/WNL.0b013e318296ea08","article-title":"Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders","volume":"80","author":"Sato","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2019.06.004_b0045","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2019.06.004_b0050","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.braindev.2019.06.004_b0055","article-title":"Persistent MOG-IgG positivity is a predictor of recurrence inMOG-IgG-associated optic neuritis, encephalitis and myelitis","volume":"12","author":"Oliveira","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.braindev.2019.06.004_b0060","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/acn3.326","article-title":"Dose-dependent inhibition of demyelination and microglia activation by IVIG","volume":"3","author":"Winter","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.braindev.2019.06.004_b0065","doi-asserted-by":"crossref","unstructured":"S. Jarius, K. Ruprecht, I. Kleiter, N. Borisow, N. Asgari, K. Pitarokoili, et al. ; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13:279.","DOI":"10.1186\/s12974-016-0717-1"},{"key":"10.1016\/j.braindev.2019.06.004_b0070","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Pr\u00f6bstel","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2019.06.004_b0075","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760418306260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760418306260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:48:02Z","timestamp":1759952882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760418306260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0387760418306260"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2019.06.004","relation":{},"ISSN":["0387-7604"],"issn-type":[{"type":"print","value":"0387-7604"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcome of a group of Japanese children with myelin-oligodendrocyte glycoprotein encephalomyelitis without preventive immunosuppressive therapy","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2019.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}